Newswise — Antibiotics are not necessary for patients after most routine endoscopic sinus surgeries despite the common practice to prescribe them, according to a team led by researchers at Massachusetts Eye and Ear.
In a new randomized controlled trial, patients who underwent endoscopic sinus surgery had no differences in outcomes including symptoms and infections whether they took an antibiotic or placebo after surgery. The only reported difference in outcomes was in side effects, with patients in the antibiotic group 10 times more likely to report symptoms like diarrhea.
The trial’s findings were published December 19 in IFAR: International Forum of Allergy & Rhinology.
“For routine sinus surgery, antibiotics are unnecessary and may cause more complications like gastrointestinal side effects” said study co-senior author Eric H. Holbrook, MD, director of the Division of Rhinology at Mass Eye and Ear and Associate Professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School. “There have been studies that have suggested antibiotics might help or maybe they don’t, and we sought to clear that up through a rigorous randomized trial.”
Randomized trial compared antibiotics and placebo
The researchers embarked on a randomized placebo-controlled trial in 2013 when they started enrolling patients at Mass Eye and Ear undergoing uncomplicated endoscopic sinus surgery. Patients without evidence of active infection during surgery were randomized to receive either a one-week regimen of an antibiotic or placebo afterwards.
A total of 77 patients (out of 134 enrolled) who met the study criteria were included in the final analysis: 37 received antibiotics and 40 did not. Patients were examined one week and six weeks after surgery.
Patients in both groups reported improvements in sinus symptoms after surgery, however there were no statistically significant differences reported in rates of infection nasal symptoms between the two groups. More than 24 percent of patients in the antibiotic group reported diarrhea compared to 2.5 percent in the placebo group.
While previous studies have looked at this issue of the utility of antibiotics after sinus surgery, there had been minimal, mixed data. This is the first study to have utilized a randomized trial to assess antibiotics on a one-week treatment duration on well-validated patient outcomes.
“Our findings suggest that otolaryngologists can rethink the practice of routinely prescribing antibiotics after endoscopic sinus surgery,” said study co-senior author Stacey T. Gray, MD, director of the Sinus Center at Mass Eye and Ear and an Associate Professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School. “Antibiotics should still be considered when the benefits outweigh the risks, including complex surgical procedures are performed or if the patient is at greater risk for developing an infection.”
Antibiotics often prescribed after sinus surgery without evidence
More than 250,000 sinus surgeries occur each year for treating chronic sinus infections that don’t respond to other medical treatment. In endoscopic sinus surgery, a scope and surgical tools are inserted into the nose to widen or open the normal drainage pathways that connect the sinuses to the nasal cavity. For people with chronic or recurrent infections, those openings can be too swollen for proper drainage.
It has long been debated whether antibiotics are routinely needed immediately after endoscopic sinus surgery to reduce risk of postoperative infections and decrease swelling, and optimize patient outcomes. A majority of sinus surgeons surveyed in previous studies reported giving antibiotics post-operatively.
Antibiotic resistance has been a long-cited concern throughout health care, especially when treating sinus infections. Unnecessary antibiotic prescriptions can also increase health care costs and impact quality of life due to related side effects.
This study only looked at routine endoscopic sinus surgery and not those that use dissolvable nasal packing, which can be a future area of study.
Co-authors in addition to Drs. Holbrook and Gray include Ashton E. Lehmann, MD, Aaishah R. Raquib, MS, Shan H. Siddiqi, MD, Josh Meier MD, and Marlene L. Durand MD, director of Infectious Diseases at Mass Eye and Ear.
About Mass Eye and Ear
Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass Eye and Ear specializes in ophthalmology (eye care) and otolaryngology–head and neck surgery (ear, nose and throat care). Mass Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 2020–2021 “Best Hospitals Survey,” U.S. News & World Report ranked Mass Eye and Ear #4 in the nation for eye care and #6 for ear, nose and throat care. For more information about life-changing care and research at Mass Eye and Ear, visit our blog, Focus, and follow us on Instagram, Twitter and Facebook.
Journal Link: IFAR: International Forum of Allergy & Rhinology